$CRDF #CRDF Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation... https://t.co/XwiU6nCbGo

@MightySoldiers @TrendSpider 

#stockmarket #stocks #charts #Daytrader #benzinga

https://t.co/DiqrEE0wHr